Cargando…
NLRP3 Inflammasome Inhibitor BAY-117082 Reduces Oral Squamous Cell Carcinoma Progression
Oral cancer is one of the most common human malignancies, and its incidence is increasing worldwide. In particular, oral squamous cell carcinoma (OSCC) is characterized by high rates of proliferation, invasiveness, and metastasis. Currently, standard treatment for OSCC includes surgical removal, che...
Autores principales: | Scuderi, Sarah Adriana, Casili, Giovanna, Basilotta, Rossella, Lanza, Marika, Filippone, Alessia, Raciti, Gabriele, Puliafito, Ivana, Colarossi, Lorenzo, Esposito, Emanuela, Paterniti, Irene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540383/ https://www.ncbi.nlm.nih.gov/pubmed/34681768 http://dx.doi.org/10.3390/ijms222011108 |
Ejemplares similares
-
Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC)
por: Casili, Giovanna, et al.
Publicado: (2023) -
Modulation of NLRP3 Inflammasome Attenuated Inflammatory Response Associated to Diarrhea-Predominant Irritable Bowel Syndrome
por: Scuderi, Sarah Adriana, et al.
Publicado: (2020) -
Beneficial effect of KYP-2047, a propyl-oligopeptidase inhibitor, on oral squamous cell carcinoma
por: Scuderi, Sarah Adriana, et al.
Publicado: (2021) -
The protective role of prolyl oligopeptidase (POP) inhibition in acute lung injury induced by intestinal ischemia-reperfusion
por: Casili, Giovanna, et al.
Publicado: (2021) -
TAK1 Inhibitor Enhances the Therapeutic Treatment for Glioblastoma
por: Campolo, Michela, et al.
Publicado: (2020)